Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01662895 · ClinicalTrials.gov registry record · Phase 2
High-Dose Deferoxamine in Intracerebral Hemorrhage
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01662895 is a Phase 2 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 42 participants.
The verdict
NCT01662895, a Phase 2 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine whether treatment with deferoxamine mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for brain hemorrhage.
Interventions
- DRUG Normal saline
- DRUG Deferoxamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-03-18 |
| Est. Completion | 2018-05-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01662895
The ClinicalTrials.gov registry entry for NCT01662895 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT01662895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01662895 about?
NCT01662895 is a clinical study titled "High-Dose Deferoxamine in Intracerebral Hemorrhage". The main purpose of this study is to determine whether treatment with deferoxamine mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for brain hemorrhage.
What is the current status of trial NCT01662895?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2013-03-18. Estimated completion is 2018-05-10.
What interventions are being tested in trial NCT01662895?
The interventions under investigation include: Normal saline (DRUG), Deferoxamine (DRUG).
Who is sponsoring clinical trial NCT01662895?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.